SPRO

0.742010.20%
AD

Amy Dix Rock

Chief Regulatory & Quality Officer

Dr. Amy Dix Rock PhD, has been the Chief Regulatory and Quality Officer at Spero Therapeutics, Inc. since October 2026. Dr. Rock served as Vice President of Clinical Development & Regulatory Affairs at Altor BioScience Corporation. Dr. Rock served as Vice President of Regulatory & Scientific Affairs at Cumberland Pharmaceuticals, Inc. since February 2016. Dr. Rock served as Senior Director of Regulatory & Scientific Affairs at Cumberland Pharmaceuticals, Inc. until February 2016. Dr. Rock joined Cumberland Pharmaceuticals, Inc., in 2001 and built its Regulatory Affairs Department and infrastructure. In addition to managing all interactions between it and The FDA, Dr. Rock oversees the preparation of pre-approval and post-approval regulatory submissions. Her additional responsibilities include involvement in protocol development and clinical trials management, overseeing Cumberland 's medical call center and supporting it corporate compliance initiatives. Dr. Rock served as Senior Scientist of Regulatory Affairs for Cumberland Pharmaceuticals, Inc. Dr. Rock has experience with basic research, having published multiple articles in peer-reviewed journals such as The Journal of Immunology, The Journal of Neurosurgery and Experimental Cell Research. She has iopharmaceutical experience spanning regulatory affairs, clinical development and quality-related functions. Most recently, she served as Senior Vice President, Regulatory Sciences at Vir Biotechnology, where she led global regulatory activities for multiple development programs, including GSK-partnered sotrovimab, a monoclonal antibody that received regulatory authorizations and approvals across multiple markets. She also supported programs that received FDA Fast Track and Breakthrough Therapy designations, as well as EMA PRIME and Orphan Drug designations. Previously, Dr. Rock held senior regulatory and clinical development leadership roles at ImmunityBio, Altor BioScience and Cumberland Pharmaceuticals, where she contributed to the development and regulatory advancement of novel immunotherapies and other pharmaceutical products. She holds a B.A. in Economics in the year 1988-1992 from Washington University, a PhD in Immunology in the year 1995-2000 from the University of Kentucky and an M.B.A. in the year 2000-2002 from The Vanderbilt Owen Graduate School of Management.

Positions